Dow Jones 12407.63 +0.00 4:44 am PST, December 27, 2006 NASDAQ 2413.51 +0.00 For info, visit access.smallcapnetwork.com S & P 500 1416.90 +0.00 Change your subscription status here Russell 2000 788.17 +0.00 VOLUME 06: ISSUE 101 Looking Back, Looking Ahead  Well it's that time of year again - a chance to look back, reflect, and then clean the slate for a new calendar year. We're particularly excited about 2007 because of some major ideas we're already working on for the SmallCap Digest (though you'll have to be patient in the meantime). Yet, we'd be amiss if we didn't publish our usual year-end recap of the past twelve months and examine its ups and downs. Hence, today's comments. Perhaps more importantly, we'll review the companies we intend to keep following.....and the ones we don't.    The Shining Star(s)  If you asked which of our 2006 ideas we thought was best, we'd have to say Commerce Planet (OTCBB: CPNE). We began our coverage back in March when the stock was trading at $0.19, then watched shares roar to as high as $1.80 by October. That was an 847% gain between the point when coverage began and the high, but even if you didn't pin-point the exact top, you still did pretty well - the current price of $1.45 is 663% above $0.19. Although the euphoria seems to have worn off a tad, we're going to keep following this one for a while. We sense there could be even more upside in store, if the stock can just get the right kind of push.  Although it wasn't 'new' to us at the time, we issued a renewed alert on CEL-SCI Corporation (AMEX: CVM) in early February when shares were priced at $0.52. Sure enough, the stock was rocketing higher within a few days, reaching $1.78 by early April. That particular move translated into a big 242% gain - not too shabby for less than two month's worth of work.  Are we keeping it on our radar? You bet! While some stocks are best 'traded', and others are best 'invested in', we think CEL-SCI shares can offer the best of both worlds. So, our coverage - which goes all the way back to 2002 - is going to continue on into at least 2007. The company's cancer treatment called Multikine holds enormous potential, and is relatively far into the development pipeline. In the meantime, we recently learned of a patent approval for an all-new treatment platform. We just see a lot of promise here for true long-term investors.  While Commerce Planet won the top honors, we don't want to forget about the trading opportunity provided to us by Clearly Canadian (OTCBB: CCBEF). After issuing our bullish opinion in January - when shares were at $2.55 - we saw a nice run to June's high of $4.55. The difference between point A and point B was a nice, refreshing 78%. Despite some recent weakness, we liked the rebuilding effort the company put together in 2006, so we're going to continue monitoring the progress. If things perk up (news-wise and stock-wise), maybe we'll re-issue an alert.    Still Optimistic  Just because a company didn't appear on the 'Shining Star' list doesn't mean we don't think it will never be there - some stocks might need more time. We think the following names are worth keeping on your watchlist, whether or not the recent stock performance has been all that great. Like we said above, timing can be everything.  Challenger Powerboats (OTCBB: CPWB), as you've read recently, is basically a reinvented company. So, we're not going to hold last year against the company, or its stock - especially after last week's big news. Shares could finally be stirring a little.  Eagle Broadband (AMEX: EAG) is in a position similar to Challenger's - its IPTV business is practically brand new. We'll stick with this name long enough to see how the venture pans out.  Siena Technologies (OTCBB: SIEN) has continued to make the most of a major acquisition from last year. Like On The Go (see below), the top line is getting bigger, and the losses are shrinking, so the company seems to be on the right path. The key difference is that these shares seem a little more responsive...at least enough for us to maintain a suggested target and stop.  Dr. Jonas Salk - yes, the same one that developed the world's first polio vaccine - was a founder of Immune Response (OTCBB: IMRP). The current management team is fully qualified to live up to his legacy. This company's work in the war against HIV is unlike almost any other, and holds tremendous potential. We feel that alone may justify owning a piece.  Multicell Technologies (OTCBB: MCET) has been quiet lately, but perhaps that's the calm before the storm. With shares just off of multi-month lows, maybe now is the ideal time to think about getting in. Remember, Multicell's "multiple opportunities to hit home-runs" could eventually include a treatment for virally-induced (like HPV) cancer in addition to its other therapies currently in testing.  We've been following BioCurex's (OTCBB: BOCX) cancer detection test (RECAF) story since 2003. Our optimistic opinion of the opportunity was largely based on RECAF's long-term potential. Since the story is far from over, BioCurex remains on our radar.  Web2 Corporation (OTCBB: WBTO) said they were going to do it, then went out and did it. The way we see it, the launch of ByIndia.com and its meteoric rise within Indian search engine rankings fully legitimizes the company (if there was anybody still unconvinced). Better still, the recent high-volume surge tells us other investors see the same potential.    Cleaning House  While we'd love to be able to follow all of our profiled companies indefinitely, fact is, it's just not feasible. It's not feasible for us because we want to focus in on only the best of the best ideas we see for our readers. And for our readers, well, it's the same story - there are only so many names you can get involved with at a time. So, in the interest of separating what we think are still the very best ideas from the rest, a little house-cleaning is in order...we're removing the following stocks from our coverage. Either they've already been too much of a let-down, or we don't foresee things significantly improving for them right away.  Though serious Internet users may be wild about the idea of social-networking, investors never really latched onto Ckrush's (OTCBB: CKRH) version of the idea. We first looked at the opportunity in July right after the entertainment company (pay per view TV, independent films) launched their networking site LiveMansion.com. The stock was at $0.29 then; now it's at $0.22. We just can't wait any longer.  You might recall a few instances in 2006 when we explained how stocks don't always reflect their respective company's performance. Well, that was largely in reference to On The Go Technologies (OTCBB: ONGO). At a corporate level, things seem to be going great - a couple of acquisitions have led to greater revenues, while relative expenses have diminished. The loss has been shrinking accordingly. Yet, shares haven't gotten any traction. They've headed lower instead...from $9.50 when we started watching it in May, to Tuesday's close of $0.35. We'd be the first to acknowledge it doesn't make a lot of sense, but who said things always make sense? For now we have to get it off our plate to make room for other companies.  For what it's worth, we think this company's corporate-level performance merits at least a little more respect from the market. However, that's just not enough to prod the stock higher right now. So -as an investment - we think we have to move on. Maybe someday things will be different.  Execute Sports (OTCBB: EXCS) went onto our coverage list in March. It had only been publicly-trading for a few days at that point, and honestly, that may have been the challenge. The story was and still is a good one, but with less than $2 million in annual sales (although that's improving too) the stock could never really draw enough investor interest.  We know for some readers these positions may be underwater right now while you're waiting for some sort of recovery. Although gains (even taxable ones) may be more fun to deal with, there still may a potential upside to bailing out in calendar 2006 - perhaps you could use the loss to offset other taxable gains. That's not our area of expertise, but the idea may be worth discussing with your tax advisor.    What's Next?  For the second year in a row, energy stocks were among the market's favorites. Of course, basic materials stocks weren't far behind, and the financials - of all things - did better than most other sectors. Healthcare lagged for most of the last twelve months, while the transportation names saved their weakness for the latter half of the year. And what do we think next year is likely to bring? Based on the sector rotation (or lack of) we see, healthcare finally looks ready for a comeback, while utilities seem to have started a pretty nice uptrend. And, we wouldn't even be surprised to see REITs continue shining despite a little weakness over the last few days. As for style, it seems to us as if growth names are finally going to get a day in the sun. Of course, we still prefer small caps over any other segment.  Regardless of what happens with all the stocks mentioned above, our mission here at the SmallCap Digest will not change in 2007 - we're going to do everything we can to bring you the very best small cap and micro cap ideas we can, and then share our best opinions about how to manage those ideas for maximum profitability. The addition of suggested targets and stops last month is one of the ways we think we can do that, but we've got a few other things we're going to be working on as well.  In any case, thanks for your support in 2006 - we appreciate it. We hope 2007 brings you even more prosperity, as we bring you even bigger and better money-making ideas. Have a great and safe holiday weekend, and we'll see you next year.      We Value Your Feedback   Got comments, questions or suggestions? Send 'em on over: Editor@smallcapnetwork.com If you wish to send a written request or inquiry, please send it to our physical address: TGR Group, LLC 4653 Carmel Mtn Rd Suite 308 #402 San Diego, CA 92130 Be a Truly Informed Investor With Free Annual Reports While there may not be a free lunch on Wall Street, free investing information isn't a bad alternative. And though the price is nice, the real benefit is how you might make more money by being able to study a potential investment with as much detail as you want. After all, knowledge is the name of the game when it comes to stocks.  The process here is simple......(1) determine the companies you'd like a complimentary annual report from, (2) complete the web-based request form, and (3) our affiliate will deliver the free reports you requested. Some are e-reports, while others are printed reports that will need to be mailed. All of them, however, include the complete overview usually desired by astute investors.  The free service provides reports on 1200 publicly traded companies, so the odds are good that you'll be able to get what you're looking for with ease. Oh, there's also no limit on the number of reports you can request, so indulge the investor inside of you as much as you'd like.  Ready to arm yourself with powerful information? Just click here.    Immune Response Ticker Changed, Along With Suggested Target & Stop You may recall from a blog entry a few days ago that the Immune Response (OTCBB: IMRP) ticker symbol was set to change following its reverse split. Well, it happened. The stock is now trading at $1.40 following the 1-for-100 split. The 'IMNR' ticker has been replaced by 'IMRP'.  Remember, the ticker will stay switched through mid-January to ensure that nobody will be confused about the post-split pricing (by the virtue of forcing them to figure out how the ticker changed). After a month or so, the plan is to revert back to the old ticker.  In the meantime, the price change also leads us to change our previously suggested target and stop. The new target is now set at $85.00, with a stop of $0.50.    New Breakthrough CEL-SCI Patent Approved Last week, CEL-SCI Corp. (AMEX: CVM) announced that a new patent had been approved. The patent is for a new immune-based disease treatment platform. The event in itself is no big deal - patents are submitted and approved all the time, even for biotech companies. The big deal in this case is that this mostly was a surprise from CEL-SCI, which had been devoting most of their effort and attention on Multikine - the company's primary cancer treatment drug currently in testing.  There are two key points we want to make in the shadow of the news. The first one is, expect good things from good companies, even when you don't hear much from them. CEL-SCI had been off the radar for quite a while, as they were reporting no news....at least on the Multikine front. Then, out of nowhere to a certain degree, they release this good news. We think it's evidence of how sometimes, you just have to have a little faith that a company is moving in the right direction.  The second point to understand is simply that new technologies should eventually mean more revenue. Yes, it may be years before the technology is monetized, but that's always the case in the biotech world. The technology is at least protected while CEL-SCI refines it before hopefully bringing it to the market. In the meantime, Multikine continues to progress.  We're not even going to pretend that we could re-explain the impressive breakthrough technology to you. We feel you're better served reading it first-hand for yourself by clicking here. We think you'll agree the idea sounds very promising.   Web2 Corp. 'ByIndia.com' Now #1 Indian Search Engine Truthfully, we're not a bit surprised, after reading about its uncanny growth. ByIndia.com, one of the creations of Web2 Corporation (OTCBB: WBTO), is now officially the #1 Indian search engine, according to Web-traffic measurement site Alexa.com. ByIndia's 800%(+) growth in just three months after its re-launch is - to us - just astounding.  If you haven't taken a look at WBTO shares, please do so. Speculative they may be, but there's some real meat to this story that other investors may find very compelling. Be sure to review all of our commentary and focused newsletters too, as they'll discuss targets, stops, and details on the things we see as critical to Web2 Corp's success.  Subscribe Information is power and timely information is profitable. Become informed and profit from SmallCapDigest Profiles and Trading Alerts by becoming a Preferred Member today. There is no cost associated with your email subscription. Add your email address below and make sure to check your email inbox and confirm your opt-in request to start receiving the SmallCapDigest Email Newsletter on a regular basis. To ensure newsletter delivery, you can add any additional email addresses you may have to the SmallCapDigest Member List. Receiving the SmallCapDigest Newsletter in multiple locations is the best way of making sure you don't miss the next investing or trading opportunity! For web based email addresses, the SmallCapDigest recommends @yahoo.com or @aol.com for timely and reliable email newsletter delivery. Subscribe Here Note: Your email address will be kept strictly confidential, and will not be shared with any other entity for any purpose at any time. If you no longer wish to receive the SmallCapDigest, simply follow the instructions located at the bottom of every SmallCapDigest Newsletter Edition. Unsubscribe Here D I S C L A I M E R: The Small Cap Digest, the Small Cap Network, its website and email newsletter (hereafter, cumulatively referred to as "SCD") , is an independent electronic publication committed to providing its readers with factual information on select publicly traded companies. SCD is owned and operated by TGR Group, LLC ("TGR"). TGR is not a registered investment advisor or broker-dealer. All companies are chosen on the basis of certain financial analysis and other pertinent criteria with a view toward maximizing the upside potential for investors while minimizing the downside risk, whenever possible.  Moreover, as detailed below, TGR accepts compensation from third party consultants and/or companies, which it features in the publication and circulation of SCD. To the degrees enumerated herein, SCD should not be regarded as an independent publication.  Click Here or go to http://access.smallcapnetwork.com/compensation_disclosure.html to view our compensation on every company we have ever covered, or visit the following web address: http://www.smallnetwork.net/profile_disclosure.html for our full profiles and http://access.smallcapnetwork.com/short_term_alerts.html for Trading Alerts.  TGR Group, LLC has been paid a fee of $30,000 cash and 100,000 shares (reverse split adjusted 12/20/06) of newly issued restricted stock by Immune Response Corp. for coverage of the Company. TGR Group LLC has been paid a fee of $15,000 by MultiCell Technologies for coverage of the company. In addition, TGR Group LLC has been pledged 100,000 warrants with an exercise price of $.60, convertible into restricted shares of Multicell, and 100,000 warrants with an exercise price of $.40, convertible into free trading shares of Mutlicell by Trilogy Capital Partners for coverage of the company. TGR Group, LLC has been paid a fee of $25,000 cash and 75,000 shares of newly issued restricted stock by Web2 Corp. for coverage of the Company. TGR Group, LLC has been paid a fee of $25,000 cash by Eagle Broadband for coverage of the Company. Ckrush, Inc. has paid TGR Group LLC a fee of $30,000 for coverage of the company. In addition, TGR Group LLC has been granted 500,000 restricted warrants convertible into common stock at $.25 by Trilogy Capital Partners. In addition, TGR Group LLC has also been granted 750,000 free trading warrants convertible into common stock at $.25 by a non-affiliated third party shareholder for coverage of Ckrush, Inc. TGR Group, LLC has been paid a fee of $30,000 cash and 20,000 shares (reverse split adjusted 08/09/06) of newly issued, restricted stock by On the Go Technologies Group for coverage of the Company. TGR Group LLC has been paid a fee of $30,000 and 200,000 newly issued restricted shares of Network Installation for coverage of the company. In addition, one of the principles of TGR Group LLC is also a principle of MarketByte LLC. In a separate contractual relationship in 2003, MarketByte LLC was paid a fee of $25,000 in cash and 500,00 newly issued, restricted shares by Network Installation for coverage of the company. The term of MarketByte's obligation to Network Installation has expired. The aforementioned 500,000 shares issued to MarketByte LLC have become free trading, and whatever number remains could be sold at anytime. This should be viewed as a potential conflict of interest. TGR Group LLC has been paid a fee of $30,000 and 300,000 newly issued restricted shares by Execute Sports for coverage of the company. In addition, one of the prinicipals of TGR Group purchased 100,000 shares of Execute Sports at a cost of $.25 per share prior to the public offering. The shares are now eligible to be free trading.That individual may choose to sell the shares at any time. This should be viewed as a potential conflict of interest. TGR Group LLC has been paid a fee of $60,000 by Commerce Planet for coverage of the company. In addition, one of the principles of TGR Group LLC is also a principle of MarketByte LLC. In a separate contractual relationship in 2004, MarketByte LLC was paid a fee of $25,000 in cash and 750,000 newly issued, restricted shares by Commerce Planet for coverage of the company. The aforementioned shares are all currently eligible to be free trading. The term of MarketByte's obligation to Commerce Planet has expired. TGR Group LLC has been paid a fee of $30,000 and pledged 150,000 warrants with an exercise price of $2, currently convertible into restricted shares of Clearly Canadian, by Level III Research, for its coverage of Clearly Canadian. TGR Group LLC has been paid a fee of $25,000 and 150,000 shares of newly issued restricted stock by Cel-Sci for coverage of the Company. Additionally, back in November of 2002, TGR Group LLC was paid a fee of $25,000 and 250,000 shares of newly issued restricted stock of Cel-Sci for coverage of the company until November of 2003. The aforementioned 250,000 restricted shares became free trading under SEC rule 144 and were sold in the open market prior to the company entering into a new contract agreement with TGR Group in February of 2006. TGR Group LLC has been paid a fee of $25,000 cash and 500,000 shares of newly issued restricted stock directly by Xtreme Companies for coverage. The aforementioned shares have become free trading under Rule 144. On March 7, 2006, TGR Group LLC entered into a contract extension whereby TGR could receive as much as $65,000 cash and 1 million, newly issued restricted shares over the next one year period from Xtreme for coverage of the company. To date, TGR has received an additional $20,000 and 250,000 newly issued restricted shares. In October of 2003, TGR Group LLC was paid a fee of $25,000 and one million newly issued restricted shares by Biocurex for coverage of the Company. Under SEC Rule 144, all one million issued restricted shares have been eligible for sale into the public market since October of 2004. In addition, on March 22, 2005, TGR entered into an extended agreement with Biocurex for a fee of 25,000 newly issued restricted shares and on July 1, 2006 TGR entered into another extended agreement with Biocurex for an additional 100,000 shares of newly issued, restricted stock. From time to time TGR sells shares received as compensation for coverage of client companies. Shares received are sold in the open market. Since the shares are received as compensation for services as previously disclosed, and not for investment purposes, TGR does not view the sale of the shares as contradictory to any opinions delivered in the content. This should be viewed as a conflict of interest by shareholders or prospective shareholders of the client companies.  TGR, its Members and Members' families, are forbidden by company policy to own, buy, sell or otherwise trade stock for their own benefit in the companies who appear in the publication unless specifically disclosed.  All statements and expressions are the sole opinions of TGR and are subject to change without notice. A profile, description, or other mention of a company within SCD is neither an offer nor solicitation to buy or sell any securities mentioned. While we believe all sources of information to be factual and reliable, in no way do we represent or guarantee the accuracy thereof, nor the statements made herein.  THE READER SHOULD VERIFY ALL CLAIMS AND DO THEIR OWN DUE DILIGENCE BEFORE INVESTING IN ANY SECURITIES MENTIONED. INVESTING IN SECURITIES IS SPECULATIVE AND CARRIES A HIGH DEGREE OF RISK. THE INFORMATION FOUND IN THIS PROFILE IS PROTECTED BY THE COPYRIGHT LAWS OF THE UNITED STATES AND MAY NOT BE COPIED, OR REPRODUCED IN ANY WAY WITHOUT THE EXPRESSED, WRITTEN CONSENT OF TGR.  We encourage our readers to invest carefully and read the investor information available at the web sites of the Securities and Exchange Commission ("SEC") at http://www.sec.gov and/or the National Association of Securities Dealers ("NASD") at http://www.nasd.com. We also strongly recommend that you read the SEC advisory to investors concerning Internet Stock Fraud, which can be found at http://www.sec.gov/consumer/cyberfr.htm. Readers can review all public filings by companies at the SEC's EDGAR page. The NASD has published information on how to invest carefully at its web site.